Mukund S. Chorghade, Ph.D., Chief Scientific Officer and Founder

Dr. Mukund Chorghade has over 25 years of experience in drug discovery, chemical route selection, process development and formulations for academic and industry-sponsored research on New Chemical Entities and generics. He currently serves as President of Chorghade Enterprises, Inc. and as Chief Scientific and Technology Officer, THINQ Pharma, where he consults for major American and European pharmaceutical companies on collaborations with worldwide academic, government and industrial laboratories.

Previously, Dr. Chorghade served as Vice President, Chemical Development Sciences at Geltex/Genzyme where he oversaw projects in transitioning New Chemical Entities from concept to commercialization (or bench to bedside). He also directed research groups at Dow Chemicals, Abbott Laboratories and CytoMed.

Dr. Chorghade earned his B.S. and M.S. degrees from the University of Poona in India. He holds a Ph.D. in organic chemistry and completed postdoctoral appointments at the University of Virginia and Harvard University, visiting scientist appointments at University of British Columbia, Vancouver, Canada and College de France / Universite’ Louis Pasteur.

Dr. Chroghade was the recipient of three “Scientist of the Year Awards” and had the honor of being a featured speaker in several national and international symposia. He has published 5 books and hundreds of articles in drug discovery and development. Dr. Chorghade serves as an adjunct faculty member at Harvard, MIT, Northeastern, Caltech and Cambridge Universities. He also serves on the board of directors of the Northeastern Section of the American Chemical Society as well as on numerous international and U.S. scientific advisory boards.